15d-PGJ2 modulates acute immune responses to Trypanosoma cruzi infection

Use of Peroxisome Proliferator‐Activated Receptor γ Agonists as Adjunctive Treatment forPlasmodium falciparumMalaria: A Randomized, Double‐Blind, Placebo‐Controlled Trial

(2009) Andrea K. Boggild et al.   CLINICAL INFECTIOUS DISEASES

PPAR-γ agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis

(2009) Márcio Y. Hassumi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell–intrinsic fashion and suppresses CNS autoimmunity

(2009) Luisa Klotz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Peroxisome Proliferator-Activated Receptor   Agonist Down-Regulates IL-17 Expression in a Murine Model of Allergic Airway Inflammation

(2009) S. J. Park et al.   JOURNAL OF IMMUNOLOGY

Rosiglitazone Modulates the Innate Immune Response toPlasmodium falciparumInfection and Improves Outcome in Experimental Cerebral Malaria

(2009) Lena Serghides et al.   JOURNAL OF INFECTIOUS DISEASES

Chagas disease, adipose tissue and the metabolic syndrome

(2009) Fnu Nagajyothi et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease

(2009) Walderez Ornelas Dutra et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

The role of parasite persistence in pathogenesis of Chagas heart disease

(2009) F. R. S. GUTIERREZ et al.   PARASITE IMMUNOLOGY

Functional IL‐10 Gene Polymorphism Is Associated with Chagas Disease Cardiomyopathy

(2008) Germano C. Costa et al.   JOURNAL OF INFECTIOUS DISEASES

Treatment of chronically Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage

(2008) Gabriela A. Medeiros et al.   MICROBES AND INFECTION